Clarient Inc announced that a manuscript based on a study of Clarient Insight®Dx Mammostrat®, a test used to classify the risk of recurrence of breast cancer following surgery and chemotherapy, will be published in an upcoming edition of Breast Cancer Research, a prominent peer-reviewed medical journal.
The manuscript, currently available in provisional format at the journal Web site, is titled "Mammostrat® as a Tool to Stratify Breast Cancer Patients at Risk of Recurrence during Endocrine Therapy."
The manuscript reports the results of a 1,540-patient study, led by John Bartlett, Professor of Molecular Pathology at the University of Edinburgh in Scotland, further validating the Mammostrat test as an aid for risk-stratifying early stage hormone receptor-treated breast cancer patients. In addition, the manuscript reports for the first time that the Mammostrat test may be useful as a tool for risk-stratifying, node-positive patients and those who do not express hormone receptors.
More than 210,000 women in the U.S. develop breast cancer each year. Mammostrat development was targeted to breast tumors which express estrogen receptor, the most commonly seen subtype of breast cancer. The standard of care for most of these patients is surgery to remove the tumor, followed by anti-hormonal therapy (eg tamoxifen or aromatase inhibitors). Mammostrat testing will help pathologists, oncologists and patients decide whether additional aggressive chemotherapy should be added to the treatment regimen.
The Mammostrat test had its origins in transcriptomic measurement of tens of thousands of genes, but Clarient scientists developed a simplified clinical grade assay by using a proteomic approach to screen hundreds of candidate markers on thousands of tissues. An optimal set of five biomarkers, able to be visualized directly on the tumor specimen, were identified which are combined using a mathematical algorithm into an assessment of risk for cancer recurrence after standard treatment. "We believe Mammostrat will bring a novel approach to tumor classification enabling pathologists to deliver a comprehensive pathological report at the time of diagnosis," said Ron Andrews, Clarient Vice Chairman and Chief Executive Officer.
"Mammostrat has now been validated in five studies involving more than 3,000 women, including comparable results in the same patient cohort used to develop and test the leading breast cancer prognostic test on the market," Andrews added. "From a commercial standpoint, Mammostrat is an example of the maturation of our breast cancer product line, strengthening our service offering to our pathology clients. It also further expands our menu of proprietary tests that personalize medicine and give patients important information for managing their disease while maintaining a good quality of life."
Professor Bartlett said, "Mammostrat is different from most risk classifiers in that it does not rely on measurement of surrogates for hormone receptor status, proliferation or tumor grade to risk-stratify. It offers the potential for a broader assessment of tumor aggressiveness by adding Mammostrat risk stratification to traditional risk classifiers."
Clarient Chief Medical Officer Ken Bloom, MD added, "Competing tests measure RNA from ground-up tumor tissue. Mammostrat measures protein expression specifically in the invasive tumor cells, ensuring biomarkers are expressed in the cells of interest, a feature that is very important in actual clinical practice. Given our strong market presence in breast cancer, these new findings will further strengthen our menu of solutions for classifying the aggressiveness of breast cancer and will allow our pathology clients to provide a more thorough assessment of each breast cancer."
